Biotech Surges 24% After Crushing Amgen In Eye Disease - Investor's Business Daily

The company's drug led to an improvement in diplopia, or double vision, an area where Amgen's Tepezza hasn't worked.

By: Investor's Business Daily

Dec 18 2024
0
0 Views

Viridian Therapeutics (VRDN) stock popped Monday after the biotech company scored a win in thyroid eye disease, a condition that causes the eyes to swell. XNOW PLAYINGHow To Buy Stocks: Swing Tradin… [+2706 chars]

Trump’s plans for EV program cuts, global tariffs and more: report - TESLARATI

Nvidia Stock Hits Sell Zone On Power-Chip Overheating Issue - Investor's Business Daily

From big tech to the media, the rush to kiss Trump’s ring is on - POLITICO

Why Super Micro Computer Stock Fell Today - Yahoo Finance

Waymo robotaxis are coming to Tokyo in 2025 - TechCrunch

Congress nears deal to rein in PBMs after years of debate - STAT

Share this page

Guest Posts by Easy Branches

Banner advertising on easybranches network